In the latest trading session, Novavax (NVAX) closed at $5.98, marking a -0.33% move from the previous day. The stock trailed the S&P 500, which registered a daily gain of 0.67%. At the same time, the ...

Bullish option flow detected in Novavax (NVAX) with 12,673 calls trading, 2x expected, and implied vol increasing almost 14 points to 90.76%. 4/11 ...

The FDA was supposed to make a final decision about approval of Novavax's COVID-19 vaccine this week, but that deadline has ...

Shares of Novavax Inc. NVAX slid 6.35% to $5.60 Thursday, on what proved to be an all-around dismal trading session for the ...

US biotech Novavax (Nasdaq: NVAX) is still waiting on a decision from the Food and Drug Administration over full approval of its protein-based COVID-19 vaccine, despite the agency having set an April ...

The FDA delays full approval for Novavax's COVID-19 vaccine, citing the need for additional data. Read more here.

The U.S. Food and Drug Administration has missed its deadline for making a decision on traditional approval for Novavax's ...

Novavax (NVAX) issued the following update on the FDA BLA for the company’s COVID-19 vaccine: “Novavax can confirm that April 1, 2025, was the ...

Novavax (NasdaqGS:NVAX) recently experienced a significant decline of 21% over the past week, coinciding with leadership changes, including the retirement of longtime Chairman James Young and the ...

Novavax (NVAX) stock rebounds 2.5% after six days of losses amid FDA approval delays for its COVID-19 vaccine.

Vaccine stocks are down after the health agency's top immunization official announced the move Monday, citing Secretary ...